Shield Therapeutics Share Discussion Threads

[husbod] 30/9/2024 10:07

Clearly word is spreading about its efficacy.All positive news.What a good reason to sell this morning....... not

[bos1234] 30/9/2024 09:14

These NHS figures are definitely interesting. Growth in 2022 and 2023 was pretty much a straight line, good but not startling. In 2024 the Growth curve has started to go exponential, with 18.5% Growth Q2 to Q1 and even higher Growth in the first month in Q3. The UK Growth rate is approaching that of the US, though obviously with much smaller revenues to STX. But it's all going in the right direction.

[dorian12] 30/9/2024 05:57

July NHS England prescription data has now been released.Another large step up.https://openprescribing.net/chemical/0901011Y0/Prescriptions have really accelerated in 2024.

[bolitix] 29/9/2024 09:05

Sorry 300 fold; not 330. Finger Trouble. i.e £30m US sales YE24 is 300x 0.1m (YE21). Of course spending went up but not anywhere near this scale. 70x more to reach their 2Bn target (if we use US Billions)! Hence, no idea why share price looks so glum; that said up 300% since that idiot CEO left

[bolitix] 27/9/2024 07:45

With a US take of 0.1m YE21 (with higher SP!!)and a 200-330 fold increase expected YE24 there are surely some great markers that not only those close to STX see. The full Texas picture should reflect better in 3Q24 showings. Cash +ve by end 25 is only a year away. Canada use stats will be out by then so should prove interesting for US.

[qipincha] 26/9/2024 21:28

we had Q2 trading update on 24th July. So we could have Q3 late Oct. only 3-4 weeks away.

[hpcg] 26/9/2024 19:58

Skcots48 - I agree. This is a small company with many years of disappointment and even a mixed 2024. Progress looks very promising but isn't definitive. Large fluctuations with magnified fear and fear of missing out are just reasonably expected.

[bos1234] 26/9/2024 19:34

hpcg, thanks for your perspective and I guess you are probably correct. Certainly the drift down recently was expected as traders banked profits aided by the MMs filling their war chests in anticipation of the pre Q3 results rise. That said I thought today's rise of over 20% in 4 hours as a bit unusual. Time will tell, but thankyou very much for your response.

[skcots48] 26/9/2024 18:38

The company won't even know their 3q figures yet so not that. Probably it just over contracted on people taking their profits and with the peds study good news it was a pile on with people not wanting to miss the bottom.... Is my guess

[hpcg] 26/9/2024 16:39

Bos1234 - I'm not sure there is any informed source behind this rise, similarly the recent pull back. It isn't entirely out of the question but the sums of money traded aren't big enough for that to be the case IMO.

[qipincha] 26/9/2024 16:21

Can’t complain a 21% rise in a day

[reviewwworld] 26/9/2024 16:13

I think copying my smart buy this morning hehe

[bos1234] 26/9/2024 16:10

So do we think somebody knows something ? RNS tomorrow ? Director buys ? Or just someone bought some and everyone else piled in ? Questions, Questions, Questions.

[wheeze] 26/9/2024 14:47

Yes, glad I topped up on Monday

[skcots48] 26/9/2024 14:39

Good bounce

[reviewwworld] 26/9/2024 10:03

Agree, I had to concede to the doom mongers a while ago. Kept my position as I was down 80% or so and left with an expensive lottery ticket.But, the doom mongers were right mostly because they could see Greg's strategy better than I could: fake it till you make it aka fk the shareholders and dilute to fund a gung-ho solo strategy.With new partnerships and new leadership, coupled with factual financial evidence that this drug is proving as popular as we thought it would and ahead of major milestones/catalysts, the probability of STX being sharply higher than current levels a year from now was too hard to ignore.

[skcots48] 26/9/2024 09:06

I was more stupid. I averaged down. We learn from our mistakes I suppose but I reluctantly had to concede Jacknife was right (I did that along time ago). But as you say the momentum has changed

[hpcg] 26/9/2024 08:51

best1467 - the company needs about 10% QoQ prescription growth in the US and a flat Europe over the next 4q to hit cash break even at the point cash runs out, at current expenses. With higher US sales there is literally more factoring capacity and that alone is probably enough. The last 2 quarters were a compound 15% but we don't quite know a) how much Texas effected Q2, b) the diversion of sales staff as mitigation. Growth in

I'm not familiar with the shape of uptake curves for new pharmaceuticals of this nature. It is a chronic condition with oral delivery but competing with existing oral and injectable alternatives. The law of small numbers means larger percentage rises are easier at the beginning, but network effects, the much greater number of second movers over fast movers, and peer group pressure are positive for acceleration. Material shows all of concave, convex and S curves as possible, which isn't helpful!

[husbod] 26/9/2024 08:12

Personally, after the debacle of the last raise, I would have thought the Board will explore every other avenue available for covering any short term cash shortfall (which probably won't exist anyway) before they look at any further dilution.

[qipincha] 26/9/2024 07:44

I have updated my estimation, if the growth is on target, Q3 revenue should be $8-10m, including the milestone income.

as far as I know, the cash position is strengthened, not sure why there is concern of fund raising, for now, this is not the case.

[reviewwworld] 26/9/2024 07:30

I've just done something stupid and swore I wouldn't do... I've bought more STX.I strongly believe the previous CEO stole defeat from the jaws of victory. The pitch here is ridiculously easy and unique. Everything that could have gone wrong, went wrong.But, feels like the tide has finally turned.

[best1467] 26/9/2024 06:41

Skcots your comments are correct but in the questions section when asked about a possibility of a further placing both agreed they had not ruled it out.
It’s all about the growth rate in the next 2Qs if they can continue at the current growth rate then it’s possible they could just avoid a further placing.
Positive news on the Korea submission and slightly lower cash burn with the Paediatric study completed along with continued impressive growth in EU royalties

[qipincha] 25/9/2024 17:29

Following the company for more than two years, some clear evidence of positive changes in recent months, since the change of the head

[photon] 25/9/2024 16:48

https://uk.advfn.com/cmn/chrt/chrt_wrap.php?epic=LSE%3Astx&name=&type=1&size=2&period=4&ind_type1=4&ind1_1=20&ind_type2=8&ind_type3=0&ma_type1=1&o_1maday1=20&o_colour1=1&olx_1=3&ma_type2=1&o_1maday2=50&o_colour2=2&olx_2=3&ma_type3=1&o_1maday3=200&o_colour3=3&olx_3=3